PTCT Ptc Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTCT

Price (delayed)

$82.13

Market cap

$6.81B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.48

Enterprise value

$6.37B

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 76
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 25

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally ...

Highlights
Ptc Therapeutics's equity has increased by 12% QoQ and by 2.9% YoY
The quick ratio has declined by 39% year-on-year but it rose by 4.1% since the previous quarter
The EPS has dropped by 133% year-on-year and by 129% since the previous quarter
The net income has plunged by 131% YoY and by 127% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ptcbio.com
Peers: FATE VRTX SRPT XNCR

Key stats

What are the main financial stats of PTCT

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
1.45%
1 week
12.09%
1 month
19.36%
1 year
65.58%
YTD
8.12%
QTD
20.55%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$827.11M
Gross profit
$764.93M
Operating income
-$58.33M
Net income
-$186.73M
Gross margin
92.5%
Net margin
-22.6%
The company's net margin has shrunk by 167% YoY and by 157% QoQ
The net income has plunged by 131% YoY and by 127% from the previous quarter
PTCT's operating margin has dropped by 118% year-on-year and by 114% since the previous quarter
The company's operating income has shrunk by 108% YoY and by 107% QoQ

Price vs fundamentals

How does PTCT's price correlate with its fundamentals

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
8.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.71
The EPS has dropped by 133% year-on-year and by 129% since the previous quarter
Ptc Therapeutics's equity has increased by 12% QoQ and by 2.9% YoY
The price to sales (P/S) is 116% higher than the last 4 quarters average of 3.8 and 110% higher than the 5-year quarterly average of 3.9
Ptc Therapeutics's revenue has plunged by 53% YoY and by 52% from the previous quarter

Efficiency

How efficient is Ptc Therapeutics business performance
Ptc Therapeutics's ROA has plunged by 127% from the previous quarter and by 123% YoY
The ROS has dropped by 118% year-on-year and by 117% since the previous quarter
The ROIC has plunged by 108% from the previous quarter and by 105% YoY

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 6% less than the total liabilities
The quick ratio has declined by 39% year-on-year but it rose by 4.1% since the previous quarter
Ptc Therapeutics's current ratio has decreased by 37% YoY but it has increased by 3.8% QoQ
PTCT's debt to equity is down by 13% since the previous quarter and by 4.3% year-on-year
Ptc Therapeutics's equity has increased by 12% QoQ and by 2.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.